[Temporary Announcement] Meifulun: Announcement of Resolutions of the 16th Meeting of the Fourth Board of Directors

Announcement number: 2026-008

Securities code: 833784 Securities abbreviation: Meifulun Sponsoring broker: SDIC Securities

Beijing Meifulun Pharmaceutical Technology Co., Ltd.

Announcement of Resolutions of the 16th Meeting of the Fourth Board of Directors

The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability for the authenticity, accuracy and completeness of the contents.

1. Meeting convening and attendance

(1) Meeting status

1. Meeting time: January 23, 2026

2. Meeting method: √On-site meeting □Electronic communication meeting

3. Meeting place: company conference room

4. Time and method of issuing board meeting notice: by email on January 13, 2026 5. Meeting host: Chairman Deng Wancai

5. Personnel attending the meeting: company supervisors and senior managers attending the meeting

6. Explanation on the legality and compliance of the convening situation:

The convening, holding and resolution review procedures of this meeting complied with the provisions of relevant laws, administrative regulations, departmental rules, normative documents and the Articles of Association.

(2) Meeting attendance

The meeting should be attended by 5 directors, and 5 directors should be present and authorized to attend.

2. Proposal review status

(1) Consideration and approval of the "Proposal on the sale of 100% equity of the wholly-owned subsidiary Beijing Meifu Xinrui Pharmaceutical Technology Co., Ltd. through public listing and transfer"

1. Contents of the motion:

Announcement number: 2026-008

For details, please refer to the "Announcement on the Proposed Transfer of Equity Interests in Wholly-Owned Subsidiaries" disclosed by the company on January 26, 2026 on the designated information disclosure platform of the National Equities Exchange and Quotations (www.neeq.com.cn) (Announcement Number: 2026-007)

2. Avoidance of voting:

There is no need to avoid voting on this motion.

3. Voting results for the motion: 5 votes in favor; 0 votes against; 0 abstentions.

4. Submit the voting status of the shareholders’ meeting:

This proposal does not need to be submitted to the shareholders' meeting for review.

3. Documents for reference

1. The "Resolution of the 16th Meeting of the 4th Board of Directors of Beijing Meifurun Pharmaceutical Technology Co., Ltd." signed and confirmed by the directors attending the meeting;

2. "Asset Valuation Report on the Equity Value of All Shareholders of Beijing Meifulun Pharmaceutical Technology Co., Ltd. involved in the proposed equity transfer of Beijing Meifulun Pharmaceutical Technology Co., Ltd." issued by Zhongqin Asset Appraisal Co., Ltd. (Zhongqin Review [2026] No. 26003).

Board of Directors of Beijing Meifulun Pharmaceutical Technology Co., Ltd.

January 26, 2026